TA155 Macular degeneration (age-related) - ranibizumab and pegaptanib: understanding NICE guidance
TA155 Macular degeneration (age-related) - ranibizumab and pegaptanib: understanding NICE guidance
TA155 Macular degeneration (age-related) - ranibizumab and pegaptanib: understanding NICE guidance (large print format)
TA155 Macular degeneration (age-related) - ranibizumab and pegaptanib: understanding NICE guidance (MS Word format)
TA155 Macular degeneration (age-related) - ranibizumab and pegaptanib: understanding NICE guidance (large print MS Word format)
TA155 Macular degeneration (age-related) - ranibizumab and pegaptanib: understanding NICE guidance (audio format)
TA155 Ranibizumab a pegaptanib ar gyfer dirywiad macwlaidd gwlyb sy'n gysylltiedig ag oedran: deall canllawiau NICE (fformat MS Word)
TA155 Ranibizumab a pegaptanib ar gyfer dirywiad macwlaidd gwlyb sy'n gysylltiedig ag oedran: deall canllawiau NICE (fformat MS Word print bras)
This page was last updated: 21 May 2012
